Alpha Mangostin and Cisplatin as Modulators of Exosomal Interaction of Ovarian Cancer Cell with Fibroblasts

Borzdziłowska, Paulina; Bednarek, Ilona

doi:10.3390/ijms23168913

Cited by 3 publications

(1 citation statement)

References 91 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It was also found that exosomes secreted from untreated tumors have a significant influence on the expression of many genes involved in functional change of fibroblasts into CAFs and in stimulation of tumor metastases. Such ability was less evident in exosomes secreted by pre-treated tumors (374). The situation is, therefore, complicated, as it seems that exosomes differ depending not only on the type of secreting cell but also on its functional status and temporal changes during therapy.…”

Section: Remarks On the Targeting Of The Tumor Microenvironmentmentioning

confidence: 99%

“DEPHENCE” system—a novel regimen of therapy that is urgently needed in the high-grade serous ovarian cancer—a focus on anti-cancer stem cell and anti-tumor microenvironment targeted therapies

Wilczyński

Paradowska

2023

Front. Oncol.

View full text Add to dashboard Cite

Ovarian cancer, especially high-grade serous type, is the most lethal gynecological malignancy. The lack of screening programs and the scarcity of symptomatology result in the late diagnosis in about 75% of affected women. Despite very demanding and aggressive surgical treatment, multiple-line chemotherapy regimens and both approved and clinically tested targeted therapies, the overall survival of patients is still unsatisfactory and disappointing. Research studies have recently brought some more understanding of the molecular diversity of the ovarian cancer, its unique intraperitoneal biology, the role of cancer stem cells, and the complexity of tumor microenvironment. There is a growing body of evidence that individualization of the treatment adjusted to the molecular and biochemical signature of the tumor as well as to the medical status of the patient should replace or supplement the foregoing therapy. In this review, we have proposed the principles of the novel regimen of the therapy that we called the “DEPHENCE” system, and we have extensively discussed the results of the studies focused on the ovarian cancer stem cells, other components of cancer metastatic niche, and, finally, clinical trials targeting these two environments. Through this, we have tried to present the evolving landscape of treatment options and put flesh on the experimental approach to attack the high-grade serous ovarian cancer multidirectionally, corresponding to the “DEPHENCE” system postulates.

show abstract

Section: Remarks On the Targeting Of The Tumor Microenvironmentmentioning

confidence: 99%